Michael A Gillette,Shankha Satpathy,Song Cao,Saravana M Dhanasekaran,Suhas V Vasaikar,Karsten Krug,Francesca Petralia,Yize Li,Wen-Wei Liang,Boris Reva,Azra Krek,Jiayi Ji,Xiaoyu Song,Wenke Liu,Runyu Hong,Lijun Yao,Lili Blumenberg,Sara R Savage,Michael C Wendl,Bo Wen,Kai Li,Lauren C Tang,Melanie A MacMullan,Shayan C Avanessian,M Harry Kane,Chelsea J Newton,MacIntosh Cornwell,Ramani B Kothadia,Weiping Ma,Seungyeul Yoo,Rahul Mannan,Pankaj Vats,Chandan Kumar-Sinha,Emily A Kawaler,Tatiana Omelchenko,Antonio Colaprico,Yifat Geffen,Yosef E Maruvka,Felipe da Veiga Leprevost,Maciej Wiznerowicz,Zeynep H Gümüş,Rajwanth R Veluswamy,Galen Hostetter,David I Heiman,Matthew A Wyczalkowski,Tara Hiltke,Mehdi Mesri,Christopher R Kinsinger,Emily S Boja,Gilbert S Omenn,Arul M Chinnaiyan,Henry Rodriguez,Qing Kay Li,Scott D Jewell,Mathangi Thiagarajan,Gad Getz,Bing Zhang,David Fenyö,Kelly V Ruggles,Marcin P Cieslik,Ana I Robles,Karl R Clauser,Ramaswamy Govindan,Pei Wang,Alexey I Nesvizhskii,Li Ding,D R Mani,Steven A Carr,Clinical Proteomic Tumor Analysis Consortium,Alex Webster,Alicia Francis,Alyssa Charamut,Amanda G Paulovich,Amy M Perou,Andrew K Godwin,Andrii Karnuta,Annette Marrero-Oliveras,Barbara Hindenach,Barbara Pruetz,Bartosz Kubisa,Brian J Druker,Chet Birger,Corbin D Jones,Dana R Valley,Daniel C Rohrer,Daniel Cui Zhou,Daniel W Chan,David Chesla,David J Clark,Dmitry Rykunov,Donghui Tan,Elena V Ponomareva,Elizabeth Duffy,Eric J Burks,Eric E Schadt,Erik J Bergstrom,Eugene S Fedorov,Ewa Malc,George D Wilson,Hai-Quan Chen,Halina M Krzystek,Hongwei Liu,Houston Culpepper,Hua Sun,Hui Zhang,Jacob Day,James Suh,Jeffrey R Whiteaker,Jennifer Eschbacher,John McGee,Karen A Ketchum,Karin D Rodland,Karna Robinson,Katherine A Hoadley,Kei Suzuki,Ki Sung Um,Kim Elburn,Liang-Bo Wang,Lijun Chen,Linda Hannick,Liqun Qi,Lori J Sokoll,Małgorzata Wojtyś,Marcin J Domagalski,Marina A Gritsenko,Mary B Beasley,Matthew E Monroe,Matthew J Ellis,Maureen Dyer,Meghan C Burke,Melissa Borucki,Meng-Hong Sun,Michael H Roehrl,Michael J Birrer,Michael Noble,Michael Schnaubelt,Michael Vernon,Michelle Chaikin,Mikhail Krotevich,Munziba Khan,Myvizhi Esai Selvan,Nancy Roche,Nathan J Edwards,Negin Vatanian,Olga Potapova,Pamela Grady,Peter B McGarvey,Piotr Mieczkowski,Pushpa Hariharan,Rashna Madan,Ratna R Thangudu,Richard D Smith,Robert J Welsh,Robert Zelt,Rohit Mehra,Ronald Matteotti,Sailaja Mareedu,Samuel H Payne,Sandra Cottingham,Sanford P Markey,Seema Chugh,Shaleigh Smith,Shirley Tsang,Shuang Cai,Simina M Boca,Sonya Carter,Stacey Gabriel,Stephanie De Young,Stephen E Stein,Sunita Shankar,Tanya Krubit,Tao Liu,Tara Skelly,Thomas Bauer,Uma Velvulou,Umut Ozbek,Vladislav A Petyuk,Volodymyr Sovenko,William E Bocik,William W Maggio,Xi Chen,Yan Shi,Yige Wu,Yingwei Hu,Yuxing Liao,Zhen Zhang,Zhiao Shi

Abstract:To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Immune subtyping revealed a complex landscape, reinforced the association of STK11 with immune-cold behavior, and underscored a potential immunosuppressive role of neutrophil degranulation. Smoking-associated LUADs showed correlation with other environmental exposure signatures and a field effect in NATs. Matched NATs allowed identification of differentially expressed proteins with potential diagnostic and therapeutic utility. This proteogenomics dataset represents a unique public resource for researchers and clinicians seeking to better understand and treat lung adenocarcinomas.

Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations

Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Multi-omics Approach to Identifying Isoform Variants As Therapeutic Targets in Cancer Patients

Prediction of Potential Drivers Connecting Different Dysfunctional Levels in Lung Adenocarcinoma Via a Protein–protein Interaction Network

Molecular Phenotypes and Potential Therapeutic Targets in Esophagogastric Adenocarcinoma Unearthed by Whole Genome and Transcriptome Analyses

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy

Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer

Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization

Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target

Integrated multi-omics analysis and machine learning to refine molecular subtypes, prognosis, and immunotherapy in lung adenocarcinoma

Functional impact of multi-omic interactions in lung cancer

Identification and validation of the mitochondrial function related hub genes by unsupervised machine learning and multi-omics analyses in lung adenocarcinoma

Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion